Protection against rotavirus disease after natural rotavirus infection

for the US Rotavirus Vaccine Efficacy Group

Research output: Contribution to journalArticlepeer-review

Abstract

Determination of protective efficacy after natural rotavirus infection is important as a basis for evaluating rotavirus vaccines. Therefore, placebo recipients in a large 2-year rotavirus vaccine trial conducted across the United States were followed to determine the protection afforded by natural rotavirus infection. Serotype 1 rotaviruses predominated (93% year 1, 66% year 2), but isolates of all four majorhuman rotavirus serotypes circulated during both years. Of the 45 placebo recipients with documented rotavirus illnesses in year 1, 1 developed rotavirus disease in year 2 compared with 29 of the other 235 placebo recipients (P =.03). Serologic data were available for 171 placebo recipients, and 37 of 140 without rotavirus illnesses in year 1 had evidence of asymptomatic rotavirus infection. None of these 37 experienced rotavirus disease in year 2 compared with 22 ofthe remaining 103 (P <.001). Overall efficacy after natural rotavirus infection was 93% (95% confidence interval, 50%-99%).

Original languageEnglish (US)
Pages (from-to)900-904
Number of pages5
JournalJournal of Infectious Diseases
Volume169
Issue number4
DOIs
StatePublished - Apr 1994

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Protection against rotavirus disease after natural rotavirus infection'. Together they form a unique fingerprint.

Cite this